Φορτώνει......
Current status of intralesional agents in treatment of malignant melanoma
Prognosis of metastatic melanoma has undergone substantial improvement with the discovery of checkpoint inhibitors. Immunotherapies and targeted therapies have improved the median overall survival (OS) of metastatic melanoma from 6 months to more than 3 years. However, still about half of the patien...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Ann Transl Med |
|---|---|
| Κύριοι συγγραφείς: | , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
AME Publishing Company
2021
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8267328/ https://ncbi.nlm.nih.gov/pubmed/34277838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-21-491 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|